STA-9090(Ganetespib) in Metastatic Ocular Melanoma

Status Completed

Clinical Trial Summary

STA-9090, a synthetic small molecule, demonstrates significant activity for down-regulating Heat Shock Protein 90 or Hsp90 levels. Hsp90 belongs to a class of molecular chaperone proteins known to be critical regulators of cancer cell proliferation and survival. Preclinical laboratory experiments have shown STA-9090, an Hsp90 inhibitor, could inhibit ocular melanoma cell lines. The primary objective of this trial is to obtain evaluations of STA-9090 efficacy to metastatic ocular melanoma.

Clinical Trial Description

Patients with metastatic ocular melanoma have a poor prognosis and very limited standard therapeutic options. The recent discoveries of GNAQ and GNA11 mutations leading to MAPK pathway activation and the over-expression of c-Met generate the hypothesis that inhibition of hsp90 client proteins will provide clinical benefit. This study tests the feasibility and efficacy of hsp90 inhibition in patients with metastatic ocular melanoma. Multiple components of the MAPK pathway (B-Raf, C-Raf, cdk4) in addition to c-Met are client proteins of hsp90 and dependent of active hsp90 for stability. Inhibition of hsp90 should lead to decreased expression of these client proteins. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01200238
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact
Status	Completed
Phase	Phase 2
Start date	September 17, 2010
Completion date	November 11, 2016

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04364230` - Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)	Phase 1/Phase 2
Completed	`NCT02858869` - Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases	Phase 1
Completed	`NCT01355120` - THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease	Phase 2
Recruiting	`NCT05524935` - Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma	Phase 2
Recruiting	`NCT05628883` - Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma	Phase 1
Active, not recruiting	`NCT05187884` - Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma	Phase 2
Recruiting	`NCT02909517` - The Role of Inflammation in Ocular Tumours
Withdrawn	`NCT00621439` - Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye	N/A
Terminated	`NCT00346372` - Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy
Recruiting	`NCT03172299` - Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma	Phase 3
Not yet recruiting	`NCT06432660` - Eye Plaque Brachytherapy for Ocular Melanoma
Completed	`NCT01893099` - Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma	Phase 1
Completed	`NCT00351728` - Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone	N/A
Active, not recruiting	`NCT03528408` - Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma	Phase 2
Completed	`NCT03052127` - Study in Subjects With Small Primary Choroidal Melanoma	Phase 1/Phase 2
Withdrawn	`NCT01930968` - Definity for Ultrasound of Intraocular Tumors
Recruiting	`NCT00168870` - Study of Metastatic Ocular Melanoma	Phase 2
Completed	`NCT02519322` - Neoadjuvant and Adjuvant Checkpoint Blockade	Phase 2
Recruiting	`NCT06007690` - A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma	Phase 3
Active, not recruiting	`NCT04417530` - Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma	Phase 2